6.90
+0.29(+4.39%)
Currency In USD
| Previous Close | 6.61 |
| Open | 6.53 |
| Day High | 7.07 |
| Day Low | 6.48 |
| 52-Week High | 39 |
| 52-Week Low | 5.36 |
| Volume | 218,157 |
| Average Volume | 114,274 |
| Market Cap | 25.41M |
| PE | -0.38 |
| EPS | -18.04 |
| Moving Average 50 Days | 7 |
| Moving Average 200 Days | 11.41 |
| Change | 0.29 |
If you invested $1000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, it would be worth $0.84 as of June 17, 2025 at a share price of $6.9. Whereas If you bought $1000 worth of Tempest Therapeutics, Inc. (TPST) shares 5 years ago, it would be worth $140.24 as of June 17, 2025 at a share price of $6.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
GlobeNewswire Inc.
Jun 05, 2025 12:00 PM GMT
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscoring the urgent need for new treatment optionsThe multiple regulatory designations were granted following strong positive result
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:05 PM GMT
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a pres